Annexon, Inc. Share Price
ANNXAnnexon, Inc. Stock Performance
Open $5.47 | Prev. Close $5.44 | Circuit Range N/A |
Day Range $5.29 - $5.55 | Year Range $1.85 - $7.16 | Volume 20,281 |
Average Traded $5.36 |
Annexon, Inc. Share Price Chart
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Annexon, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
20-May-26 | $5.00 | $5.04 | +2.65% |
19-May-26 | $4.89 | $4.91 | -1.01% |
18-May-26 | $5.30 | $4.96 | -4.62% |
15-May-26 | $5.33 | $5.20 | -2.99% |
14-May-26 | $5.42 | $5.36 | -1.56% |
13-May-26 | $5.47 | $5.45 | +0.00% |
12-May-26 | $5.58 | $5.45 | -4.31% |